Compare
Guardant Health, Inc. vs Caris Life Sciences, Inc. vs CareDx, Inc. vs Fulgent Genetics, Inc.
| Latest fiscal year | Guardant Health, Inc. GH | Caris Life Sciences, Inc. CAI | CareDx, Inc. CDNA | Fulgent Genetics, Inc. FLGT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $982.02M | $812.03M | $379.81M | $322.67M |
| Revenue growth (YoY) | +32.9% | +97.0% | +13.8% | +13.8% |
| Gross margin | 64.5% (computed) | n/a | n/a | 40.6% |
| Operating margin | -44.5% | 5.6% | -8.1% | -28.2% |
| Net margin | -42.4% | -8.4% | -5.6% | -18.8% |
| Net income | -$416.28M | -$68.09M | -$21.35M | -$60.51M |
| EPS (Diluted) | -$3.32 | -$3.22 | -$0.40 | n/a |
| Operating cash flow | -$184.76M | $83.16M | $42.03M | -$101.64M |
| Free cash flow | -$233.07M | $66.89M | n/a | -$124.21M |
| Cash & equivalents | $378.20M | $796.27M | $65.43M | $50.19M |
| Total assets | $2.01B | $1.13B | $413.23M | $1.21B |
| Total liabilities | $2.11B | $548.36M | $110.13M | $106.81M |
| Shareholders' equity | -$99.31M | $577.31M | $303.10M | $1.11B |
| Return on year-end equity | n/a | -11.8% | -7.0% | -5.4% |
| Shares outstanding | 130.64M | 282.53M | 50.92M | 31.08M |
Revenue, most recent five fiscal years
| Fiscal year | Guardant Health, Inc. | Caris Life Sciences, Inc. | CareDx, Inc. | Fulgent Genetics, Inc. |
|---|---|---|---|---|
| Latest | $982.02M Ended 2025-12-31 | $812.03M Ended 2025-12-31 | $379.81M Ended 2025-12-31 | $322.67M Ended 2025-12-31 |
| 1 year earlier | $739.02M Ended 2024-12-31 | $412.26M Ended 2024-12-31 | $333.79M Ended 2024-12-31 | $283.47M Ended 2024-12-31 |
| 2 years earlier | $563.95M Ended 2023-12-31 | $306.13M Ended 2023-12-31 | $280.32M Ended 2023-12-31 | $289.21M Ended 2023-12-31 |
| 3 years earlier | $449.54M Ended 2022-12-31 | n/a | $321.79M Ended 2022-12-31 | $618.97M Ended 2022-12-31 |
| 4 years earlier | $373.65M Ended 2021-12-31 | n/a | $296.40M Ended 2021-12-31 | $992.58M Ended 2021-12-31 |